Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 71205-525

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71205-525). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-525-30 (Image 01)

Label for Duloxetine 20 mg delayed-release capsules, packaged by Proficient Rx LP. The label indicates a quantity of 30 capsules per container. It includes details about the capsule contents, manufacturer (Actavis Elizabeth LLC), storage instructions, and a product ID QD052530. The label also shows multiple small boxes with lot, SN, and expiration placeholders.*

FDA Label Image

1 (Image 1)

FDA Label Image

Figure6 (Image 10)

A line graph depicting the percentage of patients improved based on percent improvement in pain from baseline. The graph compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo, showing higher patient improvement percentages for Duloxetine groups versus placebo across various pain improvement thresholds.*

FDA Label Image

Figure8 (Image 11)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine delayed-release 60/120 mg once daily and placebo groups. The y-axis shows the percentage of patients improved from 0 to 100%, and the x-axis shows percent improvement in pain baseline from >0% to 100% in increments. The graph depicts two lines, one with diamond markers for Duloxetine and one with cross markers for placebo, illustrating patient response differences.*

FDA Label Image

Figure9 (Image 12)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine Delayed-Release 60 mg once daily and placebo. The graph plots percentages on the y-axis and percent pain improvement on the x-axis, showing two distinct lines representing each treatment group.*

FDA Label Image

Figure10 (Image 13)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It includes two data series: Placebo marked with crosses and Duloxetine Delayed-Release 60/120 mg Once Daily marked with diamonds. The graph shows a trend of higher patient improvement percentages for Duloxetine compared to Placebo across increasing pain improvement thresholds.*

FDA Label Image

1 (Image 14)

Duloxetine 20 mg delayed release pellets capsules packaging from Proficient Rx LP. The white capsule contains small pellets visible through the clear segments, showing a two-part design with a white and transparent body. The label features the proprietary name 'Duloxetine' along with strength and dosage form details. The package is marked for oral use.*

FDA Label Image

1 (Image 2)

The image shows the packaging label for Duloxetine 20 mg delayed release pellets in capsule form. The label includes the proprietary name Duloxetine, indicates it is for oral use, and is labeled by Proficient Rx LP. The package appears to be a carton likely containing capsules.*

FDA Label Image

1 (Image 3)

An illustration showing two schematic human heads connected by an arrow pointing from one to the other, overlaid on a world map background. This likely represents information transfer or communication in a global context.*

FDA Label Image

1 (Image 4)

Chemical structure of duloxetine displayed as a molecular diagram, showing the arrangement of atoms including a tetrahydro-naphthalene ring, a thiophene group, and amine hydrochloride components as part of the molecule.*

FDA Label Image

Figure1 (Image 5)

A Kaplan-Meier survival curve chart comparing the proportion of patients with relapse over time (days) between placebo and duloxetine delayed-release capsules treatment groups. The x-axis represents time from randomization to relapse in days, and the y-axis shows the proportion of patients relapsing. The chart includes a legend distinguishing placebo (dashed line) and duloxetine delayed-release capsules (solid line).*

FDA Label Image

Figure2 (Image 6)

Kaplan-Meier survival curve showing the proportion of patients with relapse over time (days) comparing Duloxetine delayed-release capsules to placebo. The graph depicts treatment groups with Duloxetine showing a lower relapse proportion compared to placebo over approximately 300 days.*

FDA Label Image

Figure3 (Image 7)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline. It includes four lines representing different groups: Duloxetine (DUL) 60 mg BID, DUL 60 mg QD, DUL 20 mg QD, and a placebo group. The x-axis shows percent improvement in pain from baseline (0 to 100%), and the y-axis shows the percentage of patients improved (0 to 100%).*

FDA Label Image

Figure4 (Image 8)

A line graph comparing the percentage of patients improved by different doses of Duloxetine 60 mg taken twice daily (BID) and once daily (QD) versus placebo. The x-axis represents the percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. The graph includes a legend distinguishing the three groups.*

FDA Label Image

Figure5 (Image 9)

A line graph comparing percentage of patients improved against percent improvement in pain from baseline. Three groups are represented: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The graph shows higher percentages of patient improvement for both Duloxetine groups compared to placebo over the range of pain improvement percentages.*

FDA Label Image

Image2890

Duloxetine 20 mg capsules, delayed release pellets, oral dosage form. The capsules are light blue with no additional color bands. One side of the capsule is printed with a logo resembling a curved shape followed by the numbers '2890' in black ink. The capsules are shown with a metric scale background for size reference. Labeler is Proficient Rx LP.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.